NO20032573L - Nye difibroblastvekstfaktorer - Google Patents

Nye difibroblastvekstfaktorer

Info

Publication number
NO20032573L
NO20032573L NO20032573A NO20032573A NO20032573L NO 20032573 L NO20032573 L NO 20032573L NO 20032573 A NO20032573 A NO 20032573A NO 20032573 A NO20032573 A NO 20032573A NO 20032573 L NO20032573 L NO 20032573L
Authority
NO
Norway
Prior art keywords
difibroblast
new
growth factors
growth
factors
Prior art date
Application number
NO20032573A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032573D0 (no
Inventor
Peter W Bringmann
Daryl Faulds
Branislava Mitrovic
Subha Srinivasan
James Onuffer
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20032573D0 publication Critical patent/NO20032573D0/no
Publication of NO20032573L publication Critical patent/NO20032573L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20032573A 2000-12-08 2003-06-06 Nye difibroblastvekstfaktorer NO20032573L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25183700P 2000-12-08 2000-12-08
US10/005,646 US20020151496A1 (en) 2000-12-08 2001-12-07 Novel fibroblast growth factors
PCT/US2001/047350 WO2002046424A2 (en) 2000-12-08 2001-12-10 Fibroblast growth factors

Publications (2)

Publication Number Publication Date
NO20032573D0 NO20032573D0 (no) 2003-06-06
NO20032573L true NO20032573L (no) 2003-07-22

Family

ID=26674594

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032573A NO20032573L (no) 2000-12-08 2003-06-06 Nye difibroblastvekstfaktorer

Country Status (21)

Country Link
US (2) US20020151496A1 (enExample)
EP (1) EP1389237A2 (enExample)
JP (1) JP2005506275A (enExample)
KR (1) KR20040052442A (enExample)
CN (1) CN1518597A (enExample)
AU (1) AU2603402A (enExample)
BG (1) BG107888A (enExample)
BR (1) BR0116507A (enExample)
CA (1) CA2431374A1 (enExample)
CZ (1) CZ20031570A3 (enExample)
EE (1) EE200300269A (enExample)
HU (1) HUP0400657A1 (enExample)
IL (1) IL156259A0 (enExample)
MX (1) MXPA03005142A (enExample)
NO (1) NO20032573L (enExample)
PL (1) PL366158A1 (enExample)
RU (1) RU2329058C2 (enExample)
SI (1) SI21372A (enExample)
SK (1) SK7012003A3 (enExample)
WO (1) WO2002046424A2 (enExample)
ZA (1) ZA200305236B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
JP2005519891A (ja) * 2002-01-15 2005-07-07 イーライ・リリー・アンド・カンパニー 危篤状態の患者における罹病率および死亡率を低下させる方法
CA2521217C (en) * 2003-04-01 2013-05-14 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
WO2004105787A1 (en) * 2003-05-28 2004-12-09 The University Of Kyoto Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2828505T3 (es) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
SG10202100667SA (en) 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP3062881B1 (en) 2013-10-28 2019-10-02 NGM Biopharmaceuticals, Inc. Cancer models and associated methods
NZ722377A (en) 2014-01-24 2022-09-30 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN107108711B (zh) 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
WO2000060085A1 (en) * 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
JP2003512841A (ja) * 1999-10-22 2003-04-08 カイロン コーポレイション ヒトおよびラットｆｇｆ−２０遺伝子および遺伝子発現産物
DE60043197D1 (enExample) * 1999-11-18 2009-12-03 Univ Kyoto
AU2001262934A1 (en) * 2000-06-01 2001-12-11 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
EP1297012A2 (en) * 2000-07-03 2003-04-02 Curagen Corporation Novel fibroblast growth factors and nucleic acids encoding same

Also Published As

Publication number Publication date
CA2431374A1 (en) 2002-06-13
US20080057076A1 (en) 2008-03-06
RU2003119657A (ru) 2005-02-27
JP2005506275A (ja) 2005-03-03
AU2002226034A2 (en) 2002-06-18
SI21372A (sl) 2004-06-30
CZ20031570A3 (cs) 2004-01-14
NO20032573D0 (no) 2003-06-06
AU2603402A (en) 2002-06-18
EE200300269A (et) 2003-10-15
BG107888A (bg) 2004-08-31
HUP0400657A1 (en) 2006-04-28
CN1518597A (zh) 2004-08-04
BR0116507A (pt) 2004-01-06
KR20040052442A (ko) 2004-06-23
RU2329058C2 (ru) 2008-07-20
PL366158A1 (en) 2005-01-24
SK7012003A3 (en) 2004-04-06
EP1389237A2 (en) 2004-02-18
WO2002046424A2 (en) 2002-06-13
IL156259A0 (en) 2004-01-04
ZA200305236B (en) 2005-06-29
WO2002046424A3 (en) 2003-11-27
MXPA03005142A (es) 2004-10-15
US20020151496A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
NO20026064L (no) Nye forbindelser
NO20023932L (no) Nye forbindelser
NO20032573L (no) Nye difibroblastvekstfaktorer
NO20035428D0 (no) Nye anti-ineffektiver
NO20034992D0 (no) Nye 4-aninlinokinolin-3-karboksamider
PT1259508E (pt) Novos biarilcarboxamidas
DK1292733T3 (da) Kunstplæne
NO20020810D0 (no) Nye fenylpiperaziner
DK1333853T3 (da) Vækstfaktorkompleks
DK1344773T3 (da) Væksthormonsekretionsfremmere
NO20025151D0 (no) Nye forbindelser
NO20031141D0 (no) Nye forbindelser
NO20026162D0 (no) Nye forbindelser
NO20041185L (no) Nye sykloheksylsulfoner
NO20030274L (no) Nye aryleten-sulfonamider
DE60030011D1 (de) Umpflanzungsmaschine
NO20026081D0 (no) Nye forbindelser
NO20026086D0 (no) Transgent produsert plateavledet vekstfaktor
NO20013601D0 (no) Nye morfolinobenzamidsalter
NO20025902D0 (no) Nye fenylpiperaziner
DK1246934T3 (da) Mikrobielle vækstvariationer
SE0003158L (sv) Odlingsanordning
DE60133669D1 (de) Insulinähnlichen wachstumsfaktors 1
FI4625U1 (fi) Tuulikukka
NO20006308D0 (no) Dyrkingskjegle

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application